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The physiological functions and pathological roles of the Glycogen synthase kinase-type 3
(GSK3) kinases in peripheral and central systems are diverse and complex, and therefore
hard to unravel in molecular detail in vivo. Our assignment to review and discuss available
data to clarify the actual position of these kinases in the pathology of Alzheimer’s dementia
(AD) was both ambitious and easy. On the one hand, numerous studies are available in
isolated, recombinant, or cell-based systems, which have resulted in very diverse data-
sets that are hardly informative for the brain in vivo. At the other extreme, reliable, and
relevant models for the role of GSK3 in CNS are rare, if not lacking. Moreover, (too) many
in vivo studies used Li+ as “speciﬁc” inhibitor of GSK3, which is factually not valid because
lithium ions are neither speciﬁc nor potent inhibitors of GSK3 in vivo. More speciﬁc phar-
macological inhibitors of GSK3 have met with considerable problems, and are reviewed by
others in this issue or elsewhere.We concentrate here on AD-related aspects of GSK3 in
brain in vivo, mainly studied in transgenic mice and highlight some of the more important
issues, among many remaining: activation of GSK3 by amyloid, phosphorylation of protein
tau, effects on or interference with synaptic activity, differentiation between both GSK3
isoforms.These relate directly to brain function, and brain dysfunction in AD, and are to be
resolved if we want to understand the molecular pathology of this dreadful disease.
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ALZHEIMER’S DISEASE
The term dementia stems from latin words meaning “without
mind”or “de-humanized,”without any doubt the most horrifying
condition a human being can experience. Dementia comprises the
age-related deteriorationof cognitive abilities andmemory,associ-
atedwith severe changes in personality, in character, in interests (or
rather lack thereof), in social, and in general behavior. Progressive
dementia closely connects to aging and is therefore rapidly becom-
ing a prime problem for the aging populations of any nationwhere
life expectancy exceeds 65 years. In parallel with improved health
andmedical care, the ever increasing life expectancy promotes age-
related dementia as amajormedical and socio-economic problem,
next to vascular disease and cancer. It is estimated that already over
10 million people suffer dementia in Europe, and about 40 million
world-wide (data 2010). These numbers will likely double every
next 20 years (Alzheimer’s disease International; World Alzheimer
Report, 2009). Because dementing patients are to be cared for
around the clock, the number of care-takers needed in the future
will surpass all other medical needs.
While dementia is the general medical term for various dis-
eases that distort brain functioning, the most common types are
Alzheimer’s dementia (AD), vascular dementia, various types of
frontotemporal dementia (FTD) and dementia with Lewy bodies
(DLB). AD is most conspicuously named after – not by – Alois
Alzheimer,MD,who described the ﬁrst case in 1907. It is by far the
most frequent dementia, accounting for 50–70% of all cases, with
rapidly increasing incidence andprevalence. Theprevalence is only
a few percent around ages 65–69 but increases to 25–35% in octo-
genarians (Ferri et al., 2005). Despite the small fraction of cases
with early onset (before age 65), these are without doubt the most
poignant, with most severe personal, familial, and social impact.
Moreover, more women than men are becoming demented, and
apparently not only because women live longer. According to some
studies the increase is “exponential with age,” meaning that all
humans will eventually become demented when old enough – a
daunting prospect that is fortunately not yet supported by all facts.
Alzheimer’s dementia is a chronic, progressive disorder begin-
ningwithmild symptoms that are hard to recognize,mostly only in
retrospect, and as yet impossible to diagnose objectively. The end-
stage comprises very severe cognitive defects and deformed per-
sonality, inevitably evolving into complete dependence on external
care. The associated physical weakening leads eventually to death
from various causes, e.g., lung infections, stroke, coronary disease,
and cancer. The entire disease process covers extended periods of
10–20 years or more, suspected to depend on physical, genetic, and
epigenetic factors, all to be identiﬁed.
Even to date,more than a century after its ﬁrst description, and
despite massive fundamental and clinical research, AD remains
hard to diagnose. The only conclusive diagnostic tool is iden-
tical to that used by professor Alzheimer: post-mortem silver-
impregnationof brain sections, to reveal the twomainpathological
lesions, the extracellular amyloid plaques and the many neurons
ﬁlled with tangles. Importantly, and often overlooked, Alzheimer
also described the active glial processes, indicative of ongoing brain
inﬂammation, which we believe is an essential element in the
neurodegeneration process (Jaworski et al., 2009, 2010a,b, 2011).
In the absence of objective early diagnosis, AD is an exclu-
sion diagnosis by clinical examination, with initial (un-)certainty
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around 50%, when the patients’ condition is labeled “probable
AD.” Including biomarkers, i.e., biochemical in CSF or various
types of brain imaging, diagnosis is becoming gradually more
accurate, but remains statistical, yielding no more than about 80%
certainty during life. Post-mortem analysis of the brain according
toAlzheimer still remains the only certain diagnosis. Although this
might not be the most important problem faced by clinicians in
daily practice, the large margin of diagnostic uncertainty in early
phases of AD, i.e., in mild cognitive impairment (MCI), poses a
tremendous problem for clinical-phase therapeutic studies: strat-
iﬁcation of the AD population at risk is needed, by genetic and
diagnostic means.
The currently available pharmacological therapy for AD aims
largely on increasing brain acetyl-choline levels, which is totally
symptomatic. Given the rapidly rising incidence and prevalence,
development of disease-modifying therapy is overdue and must
go hand-in-hand with improved diagnosis, for reasons outlined
above. Fundamental and applied research are to be fostered to
understanding the mechanisms that cause and underlie, especially
the sporadic forms of AD, to surpass the hurdle of most current
studies and models that are largely restricted to familial, purely
genetic types of AD.
GENETICS: AMYLOID FIRST
The isolation and sequencing of amyloid peptides from brain of
AD and Down’s patients (Glenner and Wong, 1984) was the most
important biochemical ﬁnding in this ﬁeld and marks the begin-
ning of the molecular era of AD research. It allowed molecular
cloning and sequencing of the cDNA coding for their precur-
sor amyloid precursor protein (APP). In close parallel, but less
conspicuous, phosphorylated protein Tau was detected as the
major component of the intraneuronal tangled ﬁbrils observed
and described by Alzheimer (Brion, 1985; Grundke-Iqbal et al.,
1986). Both ﬁndings boosted research into these enigmatic pro-
teins, although less intense and less prominent for protein Tau
than for amyloid.
The majority of AD cases are sporadic, with onset typically
in persons over 65 years, and with “age” as the only known
determining factor. An experiment of nature turned out “for-
tunately for science”: a small fraction, 1% or less of all AD
cases are familial, purely genetic and inherited dominantly, caus-
ing early onset familial AD (EOFAD). The responsible muta-
tions have been pin-pointed to the genes coding for the APP
(12 families world-wide) and presenilins (PS1, 70+ mutations;
PS2, 7 families; Goate et al., 1991; Sherrington et al., 1995; St
George-Hyslop, 2000). These familial forms of AD are character-
ized by an age of onset between 35 and 55 years, and are most
aggressive, progressing more rapid than sporadic AD over 5–10
years.
For sporadic AD, aging is a genetically or molecularly largely
undeﬁned condition. Only one, indirect genetic factor has been
identiﬁed and stands out: the ε4 allele of the APOE gene, with an
allele frequency of 15% in the general population, but associated
to 40–50% of sporadic AD cases. The connection is again statis-
tical and again not diagnostically useful, but the effect is marked:
carriers’ risk is 5- to 10-fold higher, with an earlier age of onset
(Corder et al., 1993).
More recently, three new genes, i.e., CLU, CR1, and PICALM,
were found associated with sporadic AD in more global studies
(Harold et al., 2009; Lambert et al., 2009). These genes do not,
however, reach the statistical signiﬁcance of the ApoE4 allele, and
are yet to be studied as interesting research tools, hopefully helping
to understand the overall disease process and their contribution
to it. Nevertheless, even 17 years after the discovery of the AD–
ApoE4 connection, we still do not understand to the fullest how
this lipoprotein operates in brain, and how ApoE4 differs from
the main ApoE3 isotype in brain functions. Whether scavenging
and transport of ApoE-lipoproteins include removal of amyloid
peptides from the interstitial spaces between neurons remains to
be analyzed in detail (Castellano et al., 2011).
Genetic analysis of EOFAD cases provided knowledge of the
genes that became the starting points for all biochemical, cell-
biological and transgenic modeling of the mechanisms underlying
familial AD – and by extrapolation sporadic AD, we all hope.
These genes, i.e., APP and PS1/2, constitute the basis for the amy-
loid hypothesis posting that amyloid peptides are the prime cause
of AD.
GENETICS: A STRONG CASE FOR TAU IN
NEURODEGENERATION
Importantly, the knownEOFADcases are causedbymutations that
affect amyloidogenic processing of APP, resulting either in more
amyloid peptides, or in longer, less soluble amyloid peptides. Nev-
ertheless, these EOFAD cases are very similar to sporadic AD, and
always accompanied by severe tauopathy that is co-diagnostic for
all AD cases – even those struck at young age!
Although protein Tau is thereby inherently involved, diagnos-
tically as well as mechanistically, the recognized mutations in
the MAPT gene on chromosome 17q21 coding for protein Tau,
cause not AD but another type of dementia: FTD with parkin-
sonism, linked to chromosome 17 (FTDP-17). This sub-type of
the FTD spectrum of dementias is clinically and diagnostically
close to AD (Delacourte and Buée, 2000; Ingram and Spillantini,
2002). Tauopathies in general are a class of widely varying neuro-
degenerative diseases,all characterizedbypathological aggregation
of protein Tau in speciﬁed brain regions and types of neurons, the
most prominent of which are FTD, corticobasal degeneration and
Pick’s disease (review Sergeant et al., 2005; Ludolph et al., 2009).
Importantly, the mutations in the MAPT gene that cause the
FTDP-17 sub-type are situated not only in exons, but also in
introns. The exonicmutations give rise to the expression of mutant
protein Tau in the central neurons of patients in these FTD fami-
lies. Physiologically, Tau is subject to alternative splicing resulting
in the generation of six different isoforms, containing three or four
microtubule (MT) binding domains (Tau3R or 4R respectively)
and 0, 1, or 2 N-terminal repeats. Surprisingly, many mutations in
introns surrounding exon 10 (encoding MT-binding domain 2)
were located in, or close to the DNA signals that control mRNA
splicing. Consequently, more or less – pending the mutation –
species of wild-type protein Tau are produced containing MT-
binding domain 2, encoded by exon 10, resulting in a distorted
Tau3R/4R ratio.We can deduce fromdata in developing brainwith
mostly or even only Tau3R species expressed, that the Tau3R/4R
ratio deﬁnes or allows more axonal morphological modulation
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and plasticity. The precise consequences of the Tau3R/4R ratio in
adult and aging brain are to be deﬁned, in FTD and eventually in
AD. Despite the lack of a direct genetic link of the MAPT gene to
AD, the link might be indirect by interaction with the GSK3β gene
(Kwok et al., 2008).
In all primary tauopathies, the cognitive demise cannot but be
due to the evident progressive Tau pathology – although molec-
ularly it is not clear by what actions or mechanisms. In AD, the
co-diagnostic tauopathy is generally described as “secondary” to
amyloid pathology. The hypothesis that tauopathy is pathologi-
cally responsible in AD is supported by clinical and pathological
observations, demonstrating that the spatial and temporal pattern,
not of the amyloid but of the Tau pathology correlates most closely
with the cognitive decline in AD (Braak and Braak, 1991; Reitz
et al., 2009).MCI is themost likely prodromeof AD,but the under-
lying molecular changes and factors that mediate – or prevent
– the conversion MCI to AD are not understood. Unexpectedly,
recent pathological data demonstrate beginning tauopathy in CNS
already at young age, i.e., decades before other defects, like amy-
loid deposition become apparent (Braak and Del Tredici, 2011a,b;
Duyckaerts, 2011).
In this respect one wonders again why these dementias, even or
in particular the familial types, take decades to develop? This can
be related to, or even because of, the inherent resilience of neu-
rons and their post-mitotic nature. Alternatively, or in addition,
more than one or even more than two hits might be needed to
functionally deteriorate, and eventually kill a neuron.
TAU, A NATURALLY UNFOLDED, PHOSPHORYLATED MAP
Protein Tau was ﬁrst identiﬁed in early microtubule (MT) prepa-
rations and subsequently described to promote MT assembly,
with its designated name (τ) referring to “tubule forming” (Wein-
garten et al., 1975). The only known function of Tau is as micro-
tubule associated protein (MAP), with binding to MT regulated
by a complex interplay of isoform expression and phosphoryla-
tion. Alternative mRNA-splicing yields Tau3R or Tau4R isoforms
containing three or four MT-binding domains, as stated above
(Mandelkow et al., 1996). Phosphorylation of serine and threonine
residues is performed by kinases, with most prominent proline-
directed kinases [e.g., Glycogen synthase kinase-type 3 (GSK3),
cdk5, MAPK], and non-proline-dependent kinases (e.g., MARK,
PKA, PKC; reviews Lau et al., 2002; Johnson and Stoothoff, 2004;
Hanger et al., 2009).
While protein Tau contains a large number of serine/threonine
phosphorylation sites, only about 15 have been demonstrated to be
physiologically or pathologically important in vivo. Nevertheless,
therein hides a major analytical problem: the potential 215 differ-
ently phosphorylated sub-forms of protein Tau are impossible to
analyze individually. The balance between kinase and phosphatase
activities determines the actual level of phosphorylation of pro-
tein Tau, like for all proteins in any biological system. In contrast
to the relatively small set of kinases, the known phosphatases have
been less well-studied with respect to the function of protein Tau
in health and disease, although PP2B/calcineurin and PP2A are
potentially important (Louis et al., 2011; and references therein).
The main action of phosphorylation of protein Tau as a MAP
is in its interaction with MT: decreasing its afﬁnity for, preventing
its binding to and provoking its detachment from MT. In AD –
and in all primary tauopathies – protein Tau becomes “hyper-
phosphorylated”: rising from an average 2–5 phosphate groups
per molecule, to up to 10 phosphate groups per Tau molecule in
diseased and tangled neurons. The resulting pathological defects
aremechanistically notwell understood,but are presumed to com-
prise deregulation of MT-mediated transport, not only in axons
but also in somata and dendrites, by the aggregated Tau-ﬁbrils.
AMYLOID AND TAU IN AD: A TROUBLED RELATION. . .
Overall, the genetic ﬁndings brieﬂy summarized in previous
sections, boosted interest in protein Tau, because they made clear
that defective Tau is sufﬁcient to cause neurodegeneration and
dementia in FTD, not unlike the disease process in AD. On the
other hand, the ﬁndings also re-fueled the “amyloid-ﬁrst cascade”
hypothesis, albeit a re-phrased version: accumulation and aggre-
gation of amyloid peptides causes “also” tauopathy – by unknown
mechanisms – and thereby the clinical symptoms and pathologi-
cal defects, from mild early cognitive defects to severe dementia –
again by unknown mechanisms (Hardy and Allsop, 1991; Hardy
and Selkoe, 2002; Duyckaerts et al., 2009; Jaworski et al., 2010).
In the last decade it gradually became clear that not the
“cemented” protein-aggregates, but rather smaller, even soluble
aggregates of amyloid and Tau are synapto- and neuro-toxic
(Moechars et al., 1999; Lesné et al., 2006; Lasagna-Reeves et al.,
2011; review Jaworski et al., 2010). Indeed, the earliest cognitive
dysfunction in AD is likely caused by functional and/or struc-
tural weakening of synapses in affected limbic regions (Gonatas
et al., 1967; Hamos et al., 1989; Dekosky and Scheff, 1990). These
precede deposition and formation of solid amyloid plaques and
tangles, and neuronal loss, thereby marking MCI, or a sub-type
of MCI. We are challenged to understand this sub-type because
it is the prodromal stage of AD, and we need to deﬁne its cause:
amyloid or Tau or – most likely – both.
We now believe that synaptic dysfunction is caused by the accu-
mulation of aggregated amyloid peptides and/or soluble phospho-
rylated Tau, but their exact relation remains enigmatic and bur-
dened with questions. How do amyloid peptides in the secretory
pathway or secreted affect the cytoplasmic protein Tau? Through
a receptor for amyloid-aggregates and its downstream kinases?
Is this part of a normal physiological mechanism, or merely a
pathological problem?
The physiological relation between amyloid and Tau – if any
– is not clear in normal brain, while their pathological relation is
evident in AD brain, although complicated and still largely to be
clariﬁed. The amyloid cascade hypothesis initially posed aggrega-
tion of amyloid into plaques to cause synaptic dysfunction and
neurodegeneration. Later the Tau pathology became more promi-
nently included, still subordinate to amyloid pathology as outlined
above, and deﬁning AD as the combination of amyloid plaques
and neuroﬁbrillary tangles, conform the original description byA.
Alzheimer.
Interestingly, recent ﬁndings in experimentalmodels shed some
light on the complex relation between amyloid and Tau, in as far
as deﬁciency of protein Tau prevents amyloid-induced cognitive
defects (Roberson et al., 2007, 2011; Ittner et al., 2010; Shipton
et al., 2011). Moreover, protein Tau appears to be needed for
Frontiers in Molecular Neuroscience www.frontiersin.org August 2011 | Volume 4 | Article 17 | 3
Kremer et al. GSK3 and Alzheimer
amyloid to disrupt axonal transport in primary neurons (Vossel
et al., 2010), although in vivo conﬁrmation is needed. Addition-
ally, speciﬁc phosphorylation of protein Tau could be involved
in its mis- or re-localization from axons to the somatodendritic
compartments, and perhaps even to dendritic spines (Hoover
et al., 2010; Ittner et al., 2010; Kremer et al., submitted). These
considerations and hypotheses, although still littered with large
open spaces of unknowns, implicate kinases most deeply in the
fundamental pathological mechanism that cause AD and related
tauopathies.
For one, we showed that early in the amyloid pathology both
GSK3 isozymes become activated, as demonstrated by increased
tyrosine phosphorylation, in mouse brain in vivo (Terwel et al.,
2008). Our ﬁnding then raises the important issue of the molec-
ular mechanism by which amyloid peptides – and which species
– augment the proposedly autocatalytic tyrosine phosphorylation
of GSK3 (Cole et al., 2004; discussed below). These and related
in vivo ﬁndings ﬁrmly establish GSK3 as essentially contributing
to the pathogenesis of AD, linking amyloid to tau phosphorylation
and conﬁrming its original designation as Tau kinase I (Ishiguro
et al., 1993; Spittaels et al., 2000; Muyllaert et al., 2006, 2008; Ter-
wel et al., 2008; reviews Takashima, 2006; Jaworski et al., 2010).
Most interestingly, GSK3 is also becoming intimately implicated
in normal physiological mechanisms underlying synaptic plastic-
ity, learning, andmemory (Hooper et al., 2007; Peineau et al., 2007;
Dewachter et al., 2009; Hur and Zhou, 2010; Smillie and Cousin,
2011). Consequently, we must besides amyloid and Tau consider
direct contributions of (activated) GSK3 to synaptic defects in AD
(Figure 1; Terwel et al., 2008; Jaworski et al., 2010a,b; and references
therein).
GLYCOGEN SYNTHASE KINASE-TYPE 3
Glycogen synthase kinase-type 3 was ﬁrst described as the major
regulator of glycogenmetabolism,by phosphorylating and thereby
inhibiting glycogen synthase (Embi et al., 1980; Woodgett, 1990).
GSK3 denotes the proline-directed S/T kinases that exist as two
isozymes, GSK3α and GSK3β encoded by different genes on chro-
mosomes 19 and 3, respectively (Woodgett, 1990; Shaw et al.,
1998). The GSK3 isozymes share overall 84% sequence identity,
but 98% in the kinase domain indicating similar substrate speci-
ﬁcities (Woodgett, 1990). Nevertheless, they are functionally not
identical as demonstrated by in vitro, cellular, and in vivo data
(Hoeﬂich et al., 2000; Kaidanovich-Beilin et al., 2010; Soutar
et al., 2010). In addition to the overall similar structure, the α
isozyme contains an extended glycine-rich N-terminal region that
could deﬁne cellular localizations and interactions unique to this
isozyme (Azoulay-Alfaguter et al., 2011).
Importantly, total absence of GSK3β is embryonically lethal in
mice, implicating that GSK3α cannot compensate for the lack of
its counterpart (Hoeﬂich et al., 2000). In contrast, GSK3α can be
completely eliminated without obvious major adverse effects on
viability or health, with the possible exception of male sterility
(Kaidanovich-Beilin et al., 2010). The very different outcomes in
mice lacking either GSK3 isozyme has been attributed to differ-
ences in their mediation or regulation of transcriptional activity
by CREB, NF-κB, EGR-1, Smad3/4, or others (Liang and Chuang,
2007; Mines et al., 2011). For one, GSK3β deﬁcient mouse pups
FIGURE 1 | Schematic relations between amyloid, GSK3, proteinTau,
and other factors.The scheme depicts the activation by amyloid peptides
of GSK3α/β by increasing tyrosine phosphorylation, and leading to
increased phosphorylation of protein Tau as the central event in AD
pathogenesis. Condensed from in vivo observations in transgenic models,
both proven (solid arrows) and proposed effects (broken arrows) are
represented. The unknown molecular factors (X-factors) and mechanisms
behind the relations and connections in this scheme are not yet fully
understood as discussed in the text. Our most recent results did not
conﬁrm the proposed feedback effect of GSK3 on APP processing (data not
shown). The amyloid and pTau species that cause synaptic defects, and
eventually neurodegeneration, are not aggregates, but soluble oligomers
(marked in yellow boxes). The phosphorylation of Tau by GSK3 and other
kinases, produces a neurotoxic species, represented here asTau-P*. This
hypothetical intermediate is a soluble single, dimer, or small aggregate, in a
transitional conformational state that can be directed either into
aggregation (NFT; green box) or toward synaptic and neuronal toxicity.
Tau-P* causes synaptic dysfunction, which in various combinations with
amyloid peptides and aberrant activated GSK3 results in various synaptic
defects, initiated in the earliest phases MCI or pre-AD, and evolving to
dementia, as highlighted in the scheme. The genetic imbalance between
GSK3 andTau genes depicted in the scheme refers to the proposed
interaction between theTau (MAPT) and GSK3β genes in humans,
discussed in the text. This interaction might impact on both GSK3 activation
or availability and theTau3R/4R ratio, thereby also contributing to the
propensity of Tau phosphorylation. The imbalance is also generated in the
various single and bigenic models, discussed in the text. The combination
of all actors and factors and their interactions lead to a variety of clinical and
pathological symptoms, observed in sporadic AD patients.
most likely die because of the inability of NF-κB to regulate liver
development in the absence of GSK3β (Hoeﬂich et al., 2000)
and/or from a patterning malformation in the heart (Kerkela et al.,
2008). In general, the GSK3 isozymes affect cell survival and death,
which is of course essential, or detrimental to genesis and normal
functioning of any organ (review Mines et al., 2011).
The molecular basis for the distinct functions of both GSK3
isozymes in normal physiology remains largely unknown, which
is evidently not helping to deﬁne their similar or different roles in
pathology. Differential expression of GSK3α and GSK3β mRNA
and proteins indicate, not unexpectedly that they are subject to
different regulation in different tissues to fulﬁll diverse biologi-
cal roles. Recent advances in mice lacking one or the other GSK3
isoform, completely for GSK3α or in a cell-speciﬁc manner for
either isoform are becoming known and conﬁrm these general
impressions. For instance, mice lacking GSK3α display improved
glucose tolerance and increased glycogen synthesis as opposed to
Frontiers in Molecular Neuroscience www.frontiersin.org August 2011 | Volume 4 | Article 17 | 4
Kremer et al. GSK3 and Alzheimer
tissue-speciﬁcGSK3β knock-outmice (MacAulay et al., 2007; Patel
et al., 2008).
Recently, progress is made in understanding the physiology of
GSK3 isozymes in CNS. Both GSK3 isozymes differentially regu-
late neuronal survival, but both appear needed for axon formation,
despite acting on different substrates in brain (Kim et al., 2006,
2009; Garrido et al., 2007; Liang and Chuang, 2007; Soutar et al.,
2010). GSK3β is located throughout neuronal compartments, as
well as in astrocytes, and associated with rough endoplasmatic
reticulum, free ribosomes, mitochondria, and interestingly also
with the post-synaptic density in dendritic spines (Perez-Costas
et al., 2010). This fact links snugly to data that GSK3β medi-
ates interaction between two major forms of synaptic plasticity:
NMDA-dependent long-term potentiation (LTP) and long-term
depression (LTD). Responsible signaling mechanisms involve the
classic PI3K/AKT/GSK3 connection that regulates phosphoryla-
tion of S9 on GSK3β, and thereby its kinase activity. This link
appears as crucial in the formation of LTD or LTP, and thereby
for synaptic plasticity and cognition (Hooper et al., 2007; Peineau
et al., 2007,2008;Dewachter et al., 2009).GSK3 further contributes
toNMDA receptor trafﬁcking and functioning in cortical neurons,
again important in cognition (Chen et al., 2007). Besides these
post-synaptic actions,GSK3 also contributes to pre-synaptic func-
tions in developing and mature nerve terminals (review Smillie
and Cousin, 2011).
Several excellent reviews are concerned with various structural
and physiological functions of the GSK3 isozymes in peripheral
organs and in brain. We therefore concentrate on data – and even
more on hypotheses – that eventually link either or both GSK3
isozymes to the pathology in AD. In any case it must be remem-
bered that the GSK3α isozyme is by far the least well-studied
isoform, largely because of the historically stronger interest in
GSK3β in AD. We impose here an additional restriction by con-
centrating on data obtained in vivo,mainly in genetically modiﬁed
mice. We believe that in vivo models are the only relevant for
physiology and pathology alike, however, not without acknowl-
edging that mouse brain will never equal the complexity of human
brain.
GSK3 IN AD PATHOLOGY
The overriding hypothesis in AD maintains that amyloid pep-
tides indirectly affect the activity of phosphatases and even more
so of kinases, in particular GSK3β but also others that all con-
tribute – in concert – to the increased phosphorylation of protein
Tau typical for all tauopathies. Moreover, it is highly likely that
changes in kinase activity are an intrinsic aspect of the patholog-
ical problem, because they can and will negatively affect, or even
disrupt, other synaptic signals essential for learning and memory.
Despite considerable technical efforts, it is as yet impossible to sep-
arate and deﬁne the contributions of amyloid, of GSK3 and other
kinases, and of phosphorylated protein Tau on synaptic functions
(Figure 1).
The central role of tauopathy in AD and of the increased phos-
phorylation of protein Tau therein, was recognized early (Brion
et al., 1986; Grundke-Iqbal et al., 1986). Hyper-phosphorylated
protein Tau forms ﬁlamentous aggregates that become deposited
mainly as neuropil threads in axons anddendrites, and as the better
known neuroﬁbrillary tangles in soma of neurons in cortex and
hippocampus. The various intracellular deposits of aggregatedTau
are proposed to cause problems with all sorts of transport systems,
leading to impaired synaptic transmission, dendritic amputation,
generalized neuronal dysfunction, and eventually neurodegenera-
tion. Nevertheless, it is by no means certain that the large ﬁbrillar
aggregates are responsible, but rather the putative smaller aggre-
gates we termed “Tau-P∗” (Figure 1; Jaworski et al., 2009, 2010a,b,
2011).
In FTD the eventual hyper-phosphorylation is ascribed to the
mutation in Tau or to the distorted Tau3R/4R ratio. Nevertheless,
neither of these defects is a priori expected to evoke or solicit more
phosphorylation than wild-type Tau or than a normal isoform
ratio.Obviously,mutations in Tau or excess of one or the other iso-
form changes the molecular parameters and control mechanisms,
in as far that over a time-period of decades tau becomes phos-
phorylated to a degree that cannot be reversed. From that point
the sequence of events is rather straightforward, and well reca-
pitulated in transgenic mice: increased phosphorylation causes
conformational collapse, dimerization, and further aggregation
into ﬁbrils (Terwel et al., 2008; Patterson et al., 2011). In sporadic
AD, protein tau is not mutated, and the isoform ratio is normal,
leading to the conclusion that out-of-balance kinase activity must
explain the hyper-phosphorylation of protein tau in AD brain
(Figure 1).
GSK3β was identiﬁed in this respect as the major kinase,
denoted Tau Kinase I, ﬁrst in vitro and established ﬁrmly in vivo
in transgenic mouse brain by us (Ishiguro et al., 1993; Spittaels
et al., 2000; Takashima, 2006; Terwel et al., 2008). To date over 30
distinct phosphorylation sites are known that can potentially be
phosphorylated by GSK3β on protein Tau (Hanger et al., 2009).
Although in vivo, GSK3β appears to be the most dominant Tau
kinase, it is by nomeans the only kinase, indirectly observed in vivo
in our different transgenicmouse strains. IncreasingGSK3 activity
transgenically in itself did not cause major pathological problems
related to AD or tauopathy (Spittaels et al., 2000, 2002). Remark-
ably, increased GSK3β activity alleviated the axonopathy of our
Tau4R mice but did not cause tauopathy (Spittaels et al., 2000), in
contrast to the dramatic tauopathy evoked by the same GSK3β
transgene in combination with Tau.P301L mice, denominated
biGT mice (Terwel et al., 2008).
The former demonstrated for the ﬁrst time in vivo that GSK3
effectively phosphorylates protein Tau4R in brain, and thereby
decreased or prevented binding of Tau4R to MT to restore nor-
mal transport. Nevertheless, phosphorylation of wild-type human
Tau4R by GSK3 was not sufﬁcient to promote aggregation into
tangles (Spittaels et al., 2000). Conversely, the biGT mice demon-
strated that also Tau.P301L was effectively phosphorylated by
GSK3 in brain and to a degree sufﬁcient to form abundant tan-
gles in forebrain neurons (Terwel et al., 2008). Obviously, while
these data proved that the P301L mutation contributed addition-
ally and essentially to the aggregation of Tau in conjunction with
GSK3β, the nature of the P301L contribution to the process of Tau
aggregation is not yet revealed.
We cannot but conclude that GSK3β is a most efﬁcient Tau
kinase, needed but not sufﬁcient to force tau to aggregate into
ﬁbrils.
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DE-REGULATED GSK3 ACTIVITY IN TRANSGENIC MOUSE
BRAIN
We documented the increased tyrosine phosphorylation of both
GSK isozymes in brain of relatively young APP.V717I mice, i.e.,
at age 4–8months before their brain becomes littered with amy-
loid deposits (Moechars et al., 1999; Terwel et al., 2008). At that
age most amyloid peptides are present as small aggregates, and
inside or in close proximity of the neurons they are produced by
(Figure 2).
In brain, the regulation of the activity of GSK3α/β by phos-
phorylation of S21/S9 (inhibition) and/or Y279/216 (activation)
is a matter of controversy – not only in AD but in normal
physiology. In this respect a fundamental question refers to the
structure-function relation of both GSK3 isozymes: they are
known as S/T kinases that act on primed and non-primed sub-
strates and modulated by tyrosine phosphorylation (Y279/Y216
in GSK3α/β, respectively; review Medina and Wandosell, 2011;
references therein). Both kinases are inactivated by the well-
known serine phosphorylation (S21/S9 in GSK3α/β, respectively)
which evidently overrides activation by tyrosine phosphoryla-
tion. We cannot indulge here in extensive structural consid-
erations on the tyrosine phosphorylation, i.e., whether it is
autocatalytic or intra- or inter-molecular, which would pro-
mote GSK3 to the status of “dual activity kinases” (Cole et al.,
2004; Medina and Wandosell, 2011; references therein). Neverthe-
less, the problem is most actual and of direct interest for AD,
because of our observations in APP.V717I mice (Terwel et al.,
2008) and observations in AD patients (Leroy et al., 2007; next
section).
FIGURE 2 | Localization of amyloid peptides and pY-GSK3 in transgenic
mouse brain. (A) Intracellular amyloid (panAβ) in granules in pyramidal
neurons of CA1 (left) and cortical layers III/IV (right) in brain of APP.V717I
mice (age 6months); (B) localization of activated pY-GSK3 (green) and
panAβ (red) in the cytoplasm of CA1 neurons in the brain of APP.V717I mice
(age 6months), at right higher magniﬁcation of boxed area.
The implications are profound: amyloid peptides, which are
located in the secretory pathway or are secreted, apparently are able
to act on GSK3 to increase its tyrosine (auto-)phosphorylation,
and thereby increase the kinase activity toward protein Tau
(Figure 1). This hypothesis explains the observations in our trans-
genic and viralmodels forADwhile raising importantmechanistic
questions (reviews Jaworski et al., 2010a,b).
GSK3 IN HUMAN BRAIN, NOT ENOUGH DATA. . .
Solid data on the physiological and pathological aspects of GSK3
in healthy human brain and in neurological diseases and dementia
are rare and far apart.
In the frontal cortex of AD patients a non-signiﬁcant trend
of increased total levels of GSK3β was noted, with no differ-
ence in pS9-GSK3β. That contrasted to the signiﬁcant increase in
pY216-GSK3β (Leroy et al., 2007) recapitulated in our APP.V717I
mice, discussed in the previous section (Terwel et al., 2008). In
AD-frontal cortex pY216-GSK3 co-localized in somatodendritic
compartments with highly phosphorylated protein Tau, a ﬁnd-
ing that is not too surprising, because enzymes and substrates
must eventually meet. Neurons containing pY216-GSK3β were
evident and widespread in brain of AD patients of all Braak-stages,
from pre-tangle to stage VI, while biochemically no differences in
pS9-GSK3 were noted (Leroy et al., 2007).
This implicates pY216-GSK3β as a pathological marker for tan-
gled neurons, prevailing from early to late stages, and therefore a
likely candidate to cause, or at least contribute to the tauopathy.
Nevertheless, the mechanism behind the activating tyrosine phos-
phorylation of pY216-GSK3β in neurons destined or forced to
form tangles still eludes us, as discussed in the previous section.
In contrast, co-localization of pS9-GSK3β and Tau was evi-
dent in tangles, dystrophic neurites and neuropil threads in
AD brain, while biochemical fractionation revealed considerable
pS9-GSK3 in the sarkosyl insoluble Tau fraction (Ferrer et al.,
2002). Granulovascular degeneration, a neuronal lesion often
observed in AD, is immunoreactive for GSK3α/β and for pY216-
GSK3β. The co-localization with phosphorylated Tau (pS262,
AT100) in these granules could imply that activated pY216-
GSK3 becomes preferentially localized in special cellular com-
partments, e.g., autophagosomes, contributing to a potentially
protectivemechanism for neurons (Taelman et al., 2010; references
therein).
Tobe complete,GSK3β can also become inactive after phospho-
rylation of S389 by p38MAPK, at least in mouse brain (Thornton
et al., 2008) but no data are available for human brain. We con-
clude that we lack sufﬁcient data in healthy and diseased human
brain, to answer or counteract the questions that are raised by the
studies in transgenic models.
GSK3, APP PROCESSING, AND LI+
A further problem in this sub-ﬁeld is the eventual contribution
of GSK3 to the pathogenesis of AD in terms of increased produc-
tion of amyloid peptides. The question mainly originated from the
ﬁnding that the cytoplasmic region of APP can become phospho-
rylated,with GSK3 one of the potential kinases (Aplin et al., 1996).
Subsequently, and most amazingly, the less well-known GSK3α
isozyme was proposed to regulate amyloidogenic processing of
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APP (Phiel et al., 2003). The reported evidence was largely based
on cellular systems, using non-speciﬁc inhibitors and Li+, which
evidently do not discriminate between the GSK3 isozymes. Addi-
tionally, Li+ produces diverse pleiotropic effects in biological sys-
tems,unrelated toGSK3, even involvingNMDA-R and nitric oxide
signaling asmost recently demonstrated (reviewsAgamet al.,2009;
Ghasemi and Dehpour, 2011).
We have analyzed this issue more extensively in vivo in mouse
brain, to help deﬁne physiological functions and pathological roles
of GSK3α in normal brain and in AD-related neuronal processes
in vivo. We generated and analyzed GSK3α deﬁcient mice and
observed normal processing of endogenous murine APP, as well as
human APP produced by intracerebrally injected AAV–APP.SLA
constructs (Jaworski et al., 2009; data not shown). Moreover, we
analyzed bigenic GSK3α.KO×APP.V717I mice, yielding essen-
tially the same negative outcome. We conclude that at least the
GSK3α isozyme does not contribute signiﬁcantly to the process-
ing of APP in mouse brain in vivo. We are extending these studies
to the GSK3β isozyme, by generating mice with neuron-speciﬁc
deﬁciency of the GSK3β isozyme.
Finally, we advocate strongly against the use of lithium salts in
cell-biological and in vivo studies and even more strongly against
the generalized claim that Li+ is “a speciﬁc inhibitor” of GSK3
isozymes. Three points need to be brought to the attention of
those engaging in this direction: Li+ ions are easy to use or admin-
ister, but by no means speciﬁc inhibitors of the GSK3 isozymes,
nor does Li+ discriminate between isoforms, and lastly, Li+ is
not even a potent kinase inhibitor. We consistently ﬁnd that at
least 5mM Li+ is needed to inhibit GSK3 activity effectively in
human retinoblastoma cell-based assays,while in vivo this concen-
tration is highly toxic for mice on regimes that last for more than
a day. Moreover, while LiCl incorporated in mouse food-pellets
(2 g/kg) is not toxic for wild-type mice for up to 3months, this
diet effectively worsened the axonopathy in Tau4R mice and the
tauopathy in Tau.P301L mice, without much effect on the phos-
phorylation status of protein Tau (Muyllaert et al., 2006, 2008;
data not shown). Obviously, any effect noted using too low con-
centrations of lithium ions in any system, but particularly in vivo,
cannot be attributed to inhibition of GSK3 but must be caused
by other enzymes affected by Li+, of which more and more being
discovered (reviews Agam et al., 2009; Ghasemi and Dehpour,
2011).
CONCLUDING REMARKS: GSK3 AND PROTEIN TAU
In contrast to APP processing, the relation of GSK3 to phospho-
rylation of Tau and tauopathy became stronger than ever. Most
informative were GSK3β mice crossed with Tau4R and Tau.P301L
mice expressing wild-type or mutant human Tau, respectively
(Spittaels et al., 2000; Terwel et al., 2008), proving that GSK3β
effectively phosphorylates protein Tau in brain in vivo.
Tau.P301L mice develop tauopathy ﬁrst in their brainstem
and progressively suffer severe motor defects, eventually dying
from breathing defects and asphyxia around an average age
of 9.4months, with none surviving beyond 12months of age
(Dutschmann et al., 2010; data not shown). Interestingly, the
combination with GSK3β alleviates tauopathy in the brainstem
of Tau.P301L mice, rescuing their early mortality despite the
dramatically increased tangle-load in forebrain (Terwel et al.,
2008).
A comparable effect on Tau pathology, albeit less strong, was
apparent in the second bigenic model that combines APP.V717I
and Tau.P301L (biAT), capturing both AD pathologies in one
model (Terwel et al., 2008). A considerable fraction of biAT mice
survive longer than the parental Tau.P301L mice, although with a
strong gender effect: survivors are mostly females, but again with
more severe and aggravated Tau pathology than Tau.P301L mice.
Remarkably, the amyloid pathology in female biAT mice is com-
parable to that in the parental single transgenic APP.V717I mice
(Moechars et al., 1999; Terwel et al., 2008).
These mouse models convincingly proved that insoluble Tau
is not the neurotoxic lethal factor – at least not in mouse brain.
Because in the parental APP.V717I mice both GSK3 isozymes are
activated by increased phosphorylation of Y279/216, the similar-
ity in effects on tauopathy in both bigenic models is explained by
this increased GSK3 activity, which posts GSK3 even more ﬁrmly
as the major link between the two hallmark pathologies in AD
(Figure 1).
Overall, our studies in transgenic mouse models add consider-
able weight to the hypothesis of direct involvement of GSK3 inAD
pathogenesis, although the lack of any effect on APP processing
in vivo focuses their involvement completely onto the increased
phosphorylation of protein Tau. This outcome does, however,
not change the general sequence of events, starting with aber-
rant production of amyloid peptides that activate GSK3 kinases
to increase phosphorylation of protein Tau, as proposed by us
(Muyllaert et al., 2008; Terwel et al., 2008; Jaworski et al., 2010a,b).
Moreover, the bypass of amyloid via the activation of GSK3 to
increased phosphorylation of Tau considerably strengthens the
importance of tauopathy in the overall pathological process in
AD. The obvious condition is that we deﬁne tauopathy no longer
as the classical pathological ﬁbrillar deposits in neuronal somata
and processes, but as the phosphorylated molecular species, yet
to be identiﬁed, which we denoted as Tau-P∗ (Figure 1; Jaworski
et al., 2010a,b).
These toxic tau-species are likely dimers or small aggregates
of protein Tau, and balance between further aggregation into the
well-known large deposits that are obviously inert, or to remain
soluble and be the toxic species that cause clinical dysfunctions
known in AD patients, and in other tauopathies.
Remaining challenges are to deﬁnemolecular identity and exact
mechanisms, as well as ﬁnd the “X-factors” (Figure 1), which are
likely a combination of genetic, epigenetic, and environmental
inﬂuences, besides disease and all sorts of stress. Besides the elu-
sive Tau-species, also the amyloid peptides and aggregates, as well
as the activated GSK3 isozymes can, or rather will affect synaptic
functions. Eventually, the ﬁnal neurodegeneration will turn out
to be a combination of these different molecular players in dif-
ferent combinations, affected by different X-factors, which then
explains the large variation in clinical picture that characterizes
sporadic AD.
A ﬁnal important consideration refers to the potential of GSK3,
either or both isozymes, as therapeutic targets in dementia, AD, or
related tauopathies. Judging from available data, originating from
studies on physiology of CNS and peripheral systems, from studies
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on brain pathology, from pharmacological studies, including Li+,
from epidemiological studies, from experimental mice (transgenic
and knock-out) the prospect looks dim. GSK3 is involved in many
essential pathways in many if not all physiological systems. Phar-
macological inhibitors will have to hit the real target, i.e., GSK3
in neurons in entorhinal cortex, hippocampus, and cortex, while
GSK3 in all other cells of the human body must not be affected.
Potential alternatives, e.g., local application, or aiming at neuron-
speciﬁc interactions of GSK3 with its controlling partners, or
others that aim more speciﬁcally.
To make this happen, we need to collect more facts. . .
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